Article

Atorvastatin effectively inhibits late replicative cycle steps of SARS-CoV-2 <i>in vitro</i>

2021-03-03

Abstract excerpt

<h4>Introduction</h4> SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) has caused a pandemic of historic proportions and continues to spread worldwide. Currently, there is no effective therapy against this virus. This article evaluated the in vitro antiviral effect of Atorvastatin against SARS-CoV-2 and also identified the interaction affinity between Atorvastatin and three SARS-CoV-2 proteins, using...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1e4d00aa-51f0-5ca7-b1ce-fb04cca1e1cf
DOI: 10.1101/2021.03.01.433498

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Atorvastatin effectively inhibits late replicative cycle steps of SARS-CoV-2 <i>in vitro</i>DOI 10.1101/2021.03.01.433498Read

Computational Prediction of the Molecular Mechanism of Statin Group of Drugs Against SARS-CoV-2 PathogenesisSemantic proximity Read

Molecular Basis of SARS-CoV‑2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation ApproachesSemantic proximity Read

Existing Antiviral Options Against SARS-CoV-2 Replication in COVID-19 PatientsSemantic proximity Read

In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19Semantic proximity Read

Novel inhibitors against COVID-19 main protease suppressed viral infectionSemantic proximity Read

Inhibitors of SARS-CoV‑2 Entry: Current and Future OpportunitiesSemantic proximity Read

Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2Semantic proximity Read

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposingSemantic proximity Read

Interaction of Drug Candidates with Various SARS-CoV‑2 Receptors: An in Silico Study to Combat COVID-19Semantic proximity Read

A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samplesSemantic proximity Read

The recent outbreaks of human coronaviruses: A medicinal chemistry perspectiveSemantic proximity Read

Lancemaside A from Codonopsis lanceolata is a broad-spectrum antiviral agent against SARS-CoV-2 and variants of concernSemantic proximity Read